
Author: Vitthia Rama Murti, Registered Pharmacist (RPh 15632)
Reviewed by: Dr Yong Yi Yi, PhD in Science (Monash University), signed off 28 October 2026
Review date: 27 October 2026
Evidence grade: B
Commercial interest: Bionutricia has a commercial interest in this subject, because Bionutricia Extract sells a Black Tea (Camellia sinensis) Standardized Extract Powder. See the disclosure section.
Abstract
Background: Black tea extract powder is offered with a stated caffeine range of 0.2-0.4% and a polyphenol content above 15%. Whether such a marker range is linked to human outcomes has not been established for black tea extract.
Objective: To review the human study evidence for black tea and for caffeine- and catechin-containing tea preparations, and to state what that evidence supports about standardising caffeine and polyphenol markers in a black tea extract powder.
Methods: PubMed was searched on 27 October 2026 with two phrasings of the subject. Records were assessed from their published abstracts. Human randomised trials, meta-analyses and systematic reviews were eligible if they informed the caffeine or polyphenol question. Ten records were included: one randomised trial of black tea, six randomised trials of green tea or its extract or caffeine-containing preparations, and three reviews.
Results: The one randomised trial of black tea (PMID 24889137) gave powdered black tea solids, three cups a day, or a caffeine-matched placebo, for six months. Its abstract reports that weight gain was inhibited over three months (-0.64 kg, p = 0.047), and that these effects were no longer significant at six months. None of the included records tests a black tea extract on its own, and none reports a standardised caffeine or polyphenol range for black tea extract. The green tea trials report different catechin and caffeine doses, given in different forms and units, and their outcomes differ between trials.
Conclusion: The record supports one human trial of black tea over three to six months and a set of green tea trials showing how catechin and caffeine doses have been used in humans. It does not support a conclusion that the 0.2-0.4% caffeine range or the polyphenol figure above 15% predicts any outcome in black tea extract powder.
Review methodology
Database and search date
PubMed, searched on 27 October 2026 with the human clinical evidence filter (randomised trials, clinical trials, meta-analyses and systematic reviews).
Search terms
Search 1: black tea Camellia sinensis extract caffeine. Search 2: black tea consumption randomized trial human. Together they identified 19 distinct PMIDs.
Inclusion
A record was included only if its abstract states a caffeine or catechin amount, or a green tea dose in milligrams per day, or attributes a human result to caffeine or to a named tea constituent, or is a human trial of black tea itself. Ten records met this test: 24889137, 40314930, 28899506, 32372444, 28275131, 17882140, 22974973, 25740906, 19680234 and 35639365. Mancini (28899506) attributes green tea effects to caffeine and l-theanine given together and separately; Payne (40314930) reports outcomes for theanine plus caffeine; Lin (32372444) gives a green tea dose in milligrams per day; Bøhn (24889137) is included as the only human trial of black tea.
Exclusion
- 23235664 (Cochrane review): “green tea preparations” for weight outcomes; it gives no caffeine or catechin content.
- 32623727 (systematic review): “Fluoride absorption, transportation and tolerance mechanism in Camellia sinensis”; it addresses fluoride, not caffeine or polyphenols, and is not a human trial.
- 40126033 (meta-analysis of RCTs): flavan-3-ol interventions “included epicatechin, epigallocatechin-gallate, cocoa products, tea, grape extract, and apples”; its blood pressure and flow-mediated dilation results are pooled across these interventions, so they cannot be attributed to tea.
- 40056718 (meta-analysis): “L-theanine, a non-proteinogenic amino acid found in tea”; a single amino acid, not a marker.
- 31758301 (systematic review): “pure L-THE intake, in the form of orally administered nutritional supplements”; a single amino acid.
- 29345213 (crossover RCT): “Matcha Green Tea Drinks” made “with 1 g of Matcha premium grade”; no caffeine or catechin amount is given.
- 39213264 (RCT): “2 g of matcha” daily, with cognitive function and sleep quality as outcomes; no caffeine or catechin amount is given.
- 33461965 (RCT): a “green-Mediterranean diet” “amplified with green plant-based proteins/polyphenols as Mankai, green tea, and walnuts”; green tea cannot be separated from the other components.
- 40832777 (meta-analysis): pooled “7 RCTs and 36 cohort studies” with cancer risk as the outcome, which is outside this review’s question.
How records were assessed
Each record was read from its abstract and recorded by design, participants, population, dose and form, duration and reported outcome. Evidence was graded on a four-level A to D scale.
Summary of study findings
Bøhn et al., 2014 (PMID 24889137): black tea RCT
Design: “randomized controlled double-blind 6 month parallel-designed trial”. Participants: 111 “regular tea-drinking men and women”. Dose and form: “3 cups per day of either powdered black tea solids (tea) or a flavonoid-free flavour- and caffeine-matched placebo (control)”. Outcome: “regular ingestion of black tea over 3 months inhibited weight gain (-0.64 kg, p = 0.047)”; “These effects were no longer significant at 6 months.”
Payne et al., 2025 (PMID 40314930): systematic review and meta-analysis of RCTs
Design: “Fifty RCTs were included in the review, of which 15 were eligible for at least 1 meta-analysis”. Participants: healthy participants. Form: tea, theanine, or theanine plus caffeine. Outcome: “small-to-moderate differences … that favoured theanine plus caffeine, with regard to cognition and mood outcomes.”
Mancini et al., 2017 (PMID 28899506): systematic review of green tea
Design: systematic review of 21 studies, “4 of which were randomised controlled trials”. Form: “green tea or green tea extracts, l-theanine and epigallocatechin gallate”. Outcome: “The effects of green tea cannot be attributed to a single constituent of the beverage.”
Lin et al., 2020 (PMID 32372444): systematic review and dose-response meta-analysis of RCTs
Design: systematic review and dose-response meta-analysis of RCTs. Population: “obese subjects”. Form: green tea supplements. Outcome: body weight “WMD: -1.78 kg, 95% CI: -2.80, -0.75, p = .001”; “a more important reduction when the GT dosage was <500 mg/day and the treatment duration was of 12 weeks."
Yoneshiro et al., 2017 (PMID 28275131): randomised crossover trial
Design: “single-blinded, randomized, placebo-controlled, season-matched crossover studies”. Participants: 15 healthy male volunteers (acute) and 10 men with low brown adipose tissue activity (chronic). Dose and form: a beverage with “615 mg catechin and 77 mg caffeine”, and a placebo beverage with “82 mg caffeine”. Duration: a single ingestion, and “2 times/d for 5 wk”. Outcome: “A single ingestion of the catechin beverage increased EE in 9 subjects who had metabolically active BAT”; “Daily ingestion of the catechin beverage elevated mean ± SEM CIT … whereas the placebo beverage did not change it.”
Belza et al., 2009 (PMID 17882140): randomised crossover trial
Design: “four-way crossover, randomized, placebo-controlled, double-blind study”. Participants: 12 healthy, normal weight men. Dose and form: tablets of “500 mg GTE, 400 mg tyrosine, 50 mg caffeine, or placebo”, measured for 4 h after ingestion. Outcome: “Caffeine induced a thermogenic response of 6% above baseline value”; “The thermogenic responses to GTE and tyrosine were not significantly different from placebo.”
Hodgson et al., 2013 (PMID 22974973): placebo-controlled RCT
Design: “placebo-controlled, double-blind, randomized, parallel study”. Participants: “27 healthy physically active males” (GTE n=13; placebo n=14). Dose and form: green tea extract “1200 mg catechins, 240 mg caffeine/day” for 7 days. Outcome: “GTE did not enhance adrenergic stimulation (adrenaline and noradrenaline) during rest or exercise.”
Janssens et al., 2015 (PMID 25740906): randomised placebo-controlled trial
Design: randomised placebo-controlled study. Participants: “Sixty Caucasian men and women”. Dose and form: green tea extract “(>0.56 g/d epigallocatechin gallate + 0.28-0.45 g/d caffeine)” or placebo capsules, for 12 weeks. Outcome: “No significant differences between groups and no significant changes over time were observed for the measured variables.”
Wang et al., 2010 (PMID 19680234): randomised placebo-controlled trial
Design: randomised placebo-controlled trial over 90 days. Participants: “182 moderately overweight Chinese subjects”. Dose and form: a control drink of 30 mg catechins and 10 mg caffeine per day, and green tea arms of 458 mg/104 mg, 468 mg/126 mg and 886 mg/198 mg catechins/caffeine per day. Outcome: “a decrease in estimated intra-abdominal fat (IAF) area of 5.6 cm2 in the GT3 group”; “decreases of 1.9 cm in waist circumference and 1.2 kg body weight in the GT3 group vs. C (P < 0.05).”
Moran-Lev et al., 2023 (PMID 35639365): pilot randomised clinical trial in adolescents
Design: “Randomized clinical trial” pilot. Participants: “Forty-eight children … 18 in the coffee arm, 17 in the green tea arm, and 13 in the placebo arm”, adolescents with obesity. Dose and form: green tea “3 cups per day, total amount 252 mg catechin and 96 mg caffeine”. Duration: 6 months. Outcome: “-9.2% change in BMI in the coffee group compared with -2.3% and 0.76% in the green tea and placebo group, respectively, p = 0.002”.
Evidence-quality assessment
Grade: B. One human randomised controlled trial of black tea meets the definition of grade B, with material limits on its size, duration and test material. Grade A is not reached, because there is no meta-analysis of black tea trials and no consistent findings across more than one. Grade C is not used, because a randomised trial of black tea is among the records. Grade D is not used, because human trials were found.
Consistency. The black tea trial reports a weight and waist effect at three months that was no longer significant at six months. The green tea and caffeine trials do not agree with each other. In a single-dose study, caffeine was the only test material that was thermogenic (PMID 17882140), while the green tea extract was not. The 12-week green tea extract trial reports no significant differences between groups (PMID 25740906), and the 7-day trial reports that GTE did not enhance adrenergic stimulation (PMID 22974973).
Design and size. Of the ten records, one is a randomised trial of black tea, six are randomised trials of green tea or caffeine-containing preparations, and three are reviews, two of them meta-analyses. The black tea trial enrolled 111 participants. The other trials enrolled between 10 and 182 participants, and several crossover studies were small.
Directness. None of the included records tests a black tea extract on its own, and the black tea trial tests powdered black tea solids. None of the ten abstracts reports a standardised caffeine or polyphenol range for a black tea extract, or names theaflavins or thearubigins. The human results do not directly test the 0.2-0.4% caffeine range or the polyphenol figure above 15%.
Transfer. The green tea trials used beverages, tablets and capsules, and their doses are not given in one unit: Janssens gives grams per day, and Belza gives milligrams per tablet. None of the abstracts relates those doses to a percentage of a powder. Transfer from these populations and formats to a black tea extract powder is indirect.
Limitations
Records were assessed from their published abstracts rather than from full texts.
- Only one trial tests black tea, and it tests powdered black tea solids rather than an extract.
- No included record measures a marker range or links a caffeine or polyphenol percentage to an outcome.
- Three of the six green tea and caffeine trials enrolled fewer than 30 participants (Belza, 12; Yoneshiro, 15 and 10; Hodgson, 27).
- The black tea effect was no longer significant at six months.
- Two search phrasings with the human clinical filter were used.
Conclusion
The record supports one human trial of black tea over three to six months, comparing powdered black tea solids with a caffeine-matched placebo, and a set of green tea trials showing how catechin and caffeine doses have been used in humans. It does not support a conclusion that the 0.2-0.4% caffeine range or the polyphenol figure above 15% predicts any outcome in black tea extract powder.
References
- Bøhn SK, Croft KD, Burrows S, Puddey IB, Mulder TP, Fuchs D, et al. Effects of black tea on body composition and metabolic outcomes related to cardiovascular disease risk: a randomized controlled trial. Food & function. 2014;5(7):1613-20. PMID: 24889137. doi:10.1039/c4fo00209a
- Payne ER, Aceves-Martins M, Dubost J, Greyling A, de Roos B. Effects of Tea (Camellia sinensis) or its Bioactive Compounds l-Theanine or l-Theanine plus Caffeine on Cognition, Sleep, and Mood in Healthy Participants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrition reviews. 2025;83(10):1873-1891. PMID: 40314930. doi:10.1093/nutrit/nuaf054
- Yoneshiro T, Matsushita M, Hibi M, Tone H, Takeshita M, Yasunaga K, et al. Tea catechin and caffeine activate brown adipose tissue and increase cold-induced thermogenic capacity in humans. The American journal of clinical nutrition. 2017;105(4):873-881. PMID: 28275131. doi:10.3945/ajcn.116.144972
- Belza A, Toubro S, Astrup A. The effect of caffeine, green tea and tyrosine on thermogenesis and energy intake. European journal of clinical nutrition. 2009;63(1):57-64. PMID: 17882140. doi:10.1038/sj.ejcn.1602901
- Hodgson AB, Randell RK, Boon N, Garczarek U, Mela DJ, Jeukendrup AE, et al. Metabolic response to green tea extract during rest and moderate-intensity exercise. The Journal of nutritional biochemistry. 2013;24(1):325-34. PMID: 22974973. doi:10.1016/j.jnutbio.2012.06.017
- Janssens PL, Hursel R, Westerterp-Plantenga MS. Long-term green tea extract supplementation does not affect fat absorption, resting energy expenditure, and body composition in adults. The Journal of nutrition. 2015;145(5):864-70. PMID: 25740906. doi:10.3945/jn.114.207829
- Wang H, Wen Y, Du Y, Yan X, Guo H, Rycroft JA, et al. Effects of catechin enriched green tea on body composition. Obesity (Silver Spring, Md.). 2010;18(4):773-9. PMID: 19680234. doi:10.1038/oby.2009.256
- Mancini E, Beglinger C, Drewe J, Zanchi D, Lang UE, Borgwardt S. Green tea effects on cognition, mood and human brain function: A systematic review. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2017;34:26-37. PMID: 28899506. doi:10.1016/j.phymed.2017.07.008
- Lin Y, Shi D, Su B, Wei J, Găman MA, Sedanur Macit M, et al. The effect of green tea supplementation on obesity: A systematic review and dose-response meta-analysis of randomized controlled trials. Phytotherapy research : PTR. 2020;34(10):2459-2470. PMID: 32372444. doi:10.1002/ptr.6697
- Moran-Lev H, Cohen S, Zelber-Sagi S, Mazkeret Mayer E, Anafy A, Yerushalmy-Feler A, et al. Effect of Coffee and Tea Consumption on Adolescent Weight Control: An Interventional Pilot Study. Childhood obesity (Print). 2023;19(2):121-129. PMID: 35639365. doi:10.1089/chi.2022.0032
Disclosure of commercial interest
Bionutricia has a commercial interest in this subject. Bionutricia Extract, the ingredient supplier arm, lists “Black Tea (Camellia Sinensis) Standardized Extract Powder 0.2-0.4% Caffeine” (SKU BTEP) in its product line. Its product page states “Pure 100:1 Camellia sinensis Black Tea Extract” and “0.2-0.4% Caffeine & (>15%) Polyphenols (Bioactive Phytochemicals)”. Only these stated actives and this stated standardisation are used in this review. Bionutricia Extract supplies ingredients. Bionutricia.com, the contract manufacturer, makes finished formats; this review does not describe any finished format of this extract.
The green tea trials cited here studied green tea, a separate product in the line as “Green Tea (Camellia sinensis) Powder”. The line also lists “Fermented Black Tea (Kombucha) Powder”, which is not the extract discussed here.
This review was not commissioned or paid for by a third party. Its findings and evidence grade were not altered to favour any product. Nothing here is medical advice, and nothing in this review claims that any product treats, prevents or cures any condition.
Author biography
Vitthia Rama Murti, Registered Pharmacist (RPh 15632). Subject scope: formulation, excipients, stability, tolerability and safety, and clinical evidence including human trials, indications, dosing and clinical outcomes.
Dr Yong Yi Yi (reviewer): Dr Yong Yi Yi holds a PhD in Science from Monash University, in food science and technology, microbiology and chemistry, and a BSc (Hons) in Medical Bioscience from Monash University.
Review history
Date written: 27 October 2026, by Vitthia Rama Murti, RPh 15632.
Reviewed by: Dr Yong Yi Yi, signed off 28 October 2026.
Date reviewed: 28 October 2026, signed off by Dr Yong Yi Yi.
